Update on late-onset hypogonadism: current concepts, controversies, clinical diagnosis, pathogenesis, and treatment approaches.

Late-onset hypogonadism (LOH) has been a subject of considerable controversy since its proposal in 2002, though its status as a pathophysiological entity is undisputed.

• The underlying mechanisms of LOH remain contentious and are not fully understood.
• The review conducted a comprehensive literature review to explore ongoing controversies and challenges in the clinical diagnosis of LOH.
• The paper examines the efficacy and limitations of current therapeutic approaches, including novel anti-aging strategies and combination therapies.

Obesity is identified as the strongest risk factor for late-onset hypogonadism.

• Weight loss interventions are a current therapy targeting obesity as a risk factor for LOH.
• The efficacy of weight loss interventions is described as 'disputed' in the context of LOH treatment.
• Current therapies address only specific aspects of LOH, including weight loss interventions for obesity.

Testosterone replacement therapy (TRT) is a current treatment for LOH but carries potential health hazards.

• TRT addresses low testosterone levels as a specific aspect of LOH.
• The paper identifies 'potential health hazards associated with TRT' as a shortcoming of this treatment approach.
• TRT and weight loss interventions are described as having shortcomings that limit their overall effectiveness.

Novel anti-aging strategies have been developed based on recent discoveries and show promise in overcoming limitations of existing LOH treatments.

• Several clinical trials have substantiated the efficacy of these novel approaches.
• The anti-aging strategies are described as particularly effective when used in combination therapies.
• These innovative approaches are described as potentially offering 'more effective solutions for managing LOH.'
• The strategies aim to counteract age-related factors contributing to LOH.

Combination therapies incorporating novel anti-aging strategies show particular promise for LOH management.

• Clinical trials have substantiated the efficacy of novel approaches 'particularly when used in combination therapies.'
• The review critically examined the efficacy and limitations of current therapeutic approaches including novel anti-aging strategies and combination therapies.
• Further clinical trials are described as necessary before these approaches can be fully validated.
• Novel anti-aging strategies are described as holding 'promise for enhancing the efficacy of existing LOH treatments and overcoming their limitations.'